Prostate cancer update
Professor Peter Ekman, Stockholm, Sweden, discussed genetic and environmental factors that impact on prostate cancer incidence. He reported that obesity increases the risk of prostate cancer by 25% and that there is an increased risk from red meat and animal fat consumption of 35% and 50%, respectively. Vitamin D in the diet appears to have a protective effect and it has been shown to inhibit cell growth, both in vivo and in vitro; inhibition of c-myc oncogene by vitamin D has also been reported. A number of tumour susceptibility genes have been identi®ed, including those on chromosomes 1q and X. The gene on chromosome 1 (at 1q24-25) is present in one-third of hereditary prostate cancers, while that on chromosomes X (HPCX) is present in 5 ± 15%. An interesting observation is that polymorphisms in the androgen receptor, speci®cally the number of CAG repeats, appear related to the risk of prostate cancer. AfroAmericans have shorter CAG repeats compared with longer repeats in East Asians.
Professor Claude Schulman, Brussels, Belgium told the audience that chemoprevention for prostate cancer is a feasible objective due to the depth of knowledge on known risk factors, hormonal dependency and precursor lesions. A number of promising agents are under review, including retinoids, antiandrogens, antioestrogens, steroid aromatase inhibitors, vitamins D and E, selenium and lycopene.
Dr David Bostwick, Richmond, USA, discussed prostatic intraepithelial neoplasia (PIN), the most likely precursor of prostate cancer. PIN exists in two forms, low and high grade. The former has basal cells with nuclei of variable size, while high grade PIN is typi®ed by consistently large nuclei. The predictive value of high grade PIN for prostate cancer has been shown to be 50% at 24 months and 82% by 10 years.
Dr Judd Moul, Rockville, USA, presented an overview of the current molecular markers in prostate cancer, which includes: p53, bcl2, Ki-67 and CD-34. The multifocal nature of prostate cancer, as well as the heterogeneous nature of these markers, complicates their use. The National Cancer Institute has developed a technique called laser capture dissection to help overcome the problems of heterogeneity in prostate tumours. This allows small foci of cancer to be targeted and changes at the cellular level detected using mutational analysis and sequencing. Mutations in the p53 gene have been identi®ed in 4 ± 79% of prostate cancers, but the signi®-cance of this marker remains controversial. Dr Moul's group has shown that focal p53 expression in the primary tumour is predictive of cancer recurrence following radical prostatectomy; disease free survival at six years was 75% in men with a normal p53 gene compared with 39.3% in men with abnormalities in the gene.
Work on the bcl-2 gene by Brawer and associates indicates that the gene is positively correlated with recurrence following radical prostatectomy. Disease-free survival was 61% at six years in 118 patients who were bcl-2 negative compared with 15% in 44 patients who were bcl-2 positive.
Dr Mike Brawer, Seattle, USA, presented data on the use of complexed prostate-speci®c antigen (cPSA). Findings from his institute suggest that cPSA offers equivalent or superior enhancement of speci®city as the freeatotal PSA assay. A multicentre study showed that speci®cities at 95% sensitivity for total PSA, cPSA and freeatotal PSA were 18%, 24% and 23%, respectively. cPSA has the added bene®t of being a less expensive test than freeatotal PSA as a single assay is involved. cPSA has been approved by the Food and Drug Administration for the monitoring of men with established malignancy.
Dr Bob Djavan, Vienna, Austria, discussed the value of repeat biopsies in conjunction with PSA level in prostate cancer detection. His research shows that an additional 10% of cancers can be detected with a second biopsy in men with PSA levels 4 ± 10 ngaml. With regard to PSA detection, the most accurate predictors of prostate cancer were percent free PSA and PSA density of the transition zone (PSA-TZ). At a cut-off of 30%, percent free PSA had a sensitivity of 90% and a speci®city of 50%. The sensitivity and speci®city of PSA-TZ at a cut-off of 0.26 ngamlaml was 78% and 52%, respectively.
Prostate size was also a factor in detection, with more cancers being found in larger glands (40 ml). High-grade PIN was an indication for repeat biopsy, but with lowgrade PIN, repeat biopsy should be performed if PSA level is >10 ngaml. It was also recommended that in repeat biopsies, the number of cores taken should be increased and the biopsy site should include the transition zone and the posterolateral region.
Professor Fritz Schro È der, Rotterdam, The Netherlands, pointed out to the delegates that screening for prostate cancer was still controversial. Data from the European Randomized Study of Screening for Prostate Cancer (ERSPC) show that at the time of the prevalence screen almost 30% of men had tumours that were too large for cure. This ®ve-year study involving 8000 men indicates that the positive predictive value for cancer in the PSA range 0 ± 3.9 ngaml was 9.7% (i.e. approximately 10 biopsies to detect one cancer) and 25.4% in the range 3.0 ± 3.9 ngaml. More recent data show that in the PSA range 2 ± 4 ngaml, almost 80% of cancers would be expected to be histologically con®ned to the prostate and 50% would have aggressive histological characteristics (Gleason score 7). In conclusion, Professor Schro È der suggested that the optimal PSA level for biopsy is still to be determined; however, biopsy in men with PSA 3 ngaml has been validated.
Dr Alan Partin, Baltimore, USA, presented data from a study at the Johns Hopkins Hospital on the natural history of progression following radical prostatectomy (JAMA, 1999) . A total of 1997 men who underwent radical prostatectomy were followed with PSA assays and DRE examination at three month intervals for the ®rst year, twice a year for the second year and then annually thereafter. PSA of 0.2 ngaml or more was evidence of biochemical recurrence. Results show that actuarial metastasis-free survival for all men was 82% (range: 76 ± 88%) at 15 years after surgery. Biochemical recurrence occurred in 315 (15%) men; metastatic disease developed within the study period in 103 of the 304 men who did not receive hormonal treatment. The median actuarial time to metastases was eight years from the time of PSA elevation. The median actuarial time to death after developing metastatic disease was ®ve years. He added that time to biochemical progression (P < 0.001), Gleason score (P < 0.001) and PSA doubling time (P < 0.001) were predictive of the probability and time to the development of metastatic disease. An algorithm based on these parameters could be constructed to stratify men into risk groups. The time interval from surgery to the appearance of metastatic disease was predictive of time until death (P < 0.02).
Professor Frans Debruyne, Nijmegen, The Netherlands, reviewed the current status of antiandrogen monotherapy for prostate cancer. In terms of prolonging progression free survival,¯utamide may be as effective as orchidectomy. Experience with nilutamide monotherapy is limited and its use could be restricted due to the high incidence of drug-related side-effects. Bicalutamide, 50 mgaday, has been shown to be inferior to castration in M disease, but at 150 mgaday, it is equivalent to castration inM 0 disease. However, quality of life with bicalutamide was better than with castration. Professor Debruyne suggested that antiandrogen monotherapy may have a role in younger men where sexual potency is an important factor.
Professor Hartwig Huland, Hamburg, Germany, discussed the ability to predict extracapsular spread of prostate cancer. His group has assessed the impact of speci®c parameters on capsular penetration using a multivariate Classi®cation and Regression Tree (CART) analysis. Prediction of preoperative pT2 disease was made on the basis of clinical stage, transrectal ultrasonography, PSA, Gleason grade, number of positive biopsies and number of biopsies containing Gleason grade 4a5. The results of the CART analysis showed that number of biopsies with high grade cancer, PSA and number of positive biopsies reached signi®cance level. The remaining parameters were not independent predictors of organcon®ned disease. In patients with 1 biopsy containing high-grade cancer and a PSA level of < 10 ngaml, the likelihood of pT2 cancer was 86%.
Dr Alexandre Zlotta, Brussels, Belgium, presented information on the problems of positive margins following radical prostatectomy. The incidence of positive margins has been shown to vary widely, from 5% in T1a disease to 53% in T3 disease. Location is also related to disease stage; in T1 disease, it is mostly at the apex compared with a posterolateral position in T3 disease. In terms of progression, survival is related to the number of positive margins and their location; worse case is a posterolateral position. Fesseha and co-workers have recently shown that prognosis with a positive apical margin is the same as with no positive margin.
There is apparently no consensus on treatment for positive margins. Options include adjuvant external radiotherapy or hormonal treatment and surveillance with delayed radiotherapy or hormonal treatment. A 70 ± 91% ®ve-year survival rate with adjuvant radiotherapy has been demonstrated compared with 46 ± 50% with no radiotherapy. Hormonal therapy with¯utamide in pT3 disease has resulted in a progression-free survival rate at four years of 90% versus 69% in the control.
Dr Peter Iversen, Copenhagen, Denmark, presented an overview of the use of hormonal therapy in prostate cancer. Hormonal therapy can be used in both local and locally advanced cancer as neoadjuvant to radical prostatectomy or radiotherapy. In cT1 ± 2 disease, neoadjuvant hormonal therapy has consistently been shown to reduce positive margins, as well as reduce the incidence of PIN. However, no signi®cant improvement in time to PSA progression or survival have been noted.
Hormonal therapy as a neoadjuvant to radiotherapy has demonstrated a number of bene®ts. Target volume has been decreased, resulting in reduced side effects of radiotherapy; radiosensitivity can be increased and control of micrometastatc disease achieved. RTOG 8610 has examined neoadjuvant hormonal therapy with radiotherapy and shown that ®ve-year local disease progression was 46% with hormonal therapy versus 71% in the control. Progression-free survival was improved with hormonal therapy, although no survival advantage was shown. However, a survival advantage of luteinising hormone-releasing hormone agonist therapy with radiotherapy at three years has been shown in a study by Bolla.
Advantages of early hormonal therapy over deferred treatment have been demonstrated in patients with nonmetastatic early disease. A number of studies in this Hormonal escape disease is a major problem in prostate cancer. Professor Andrzej Borowski, Warsaw, Poland, discussed the various treatment options that can be considered for this group of patients. The ®rst-line strategy is androgen withdrawal, which takes advantage of the androgen withdrawal syndrome, the median duration of which is four months, although no signi®cant survival advantage has been shown. Orchidectomy has proven useful in 20% of patients; oestrogens are also under study in phase III trials.
Chemotherapy in hormone escaped disease has limited effectiveness due to the low proliferation rate of prostate cancer cells. A response rate of 33% has been demonstrated with adriamycin in metastatic disease; this is increased to 84% if stable disease is included. Cisplatin is associated with response rates of 0 ± 33%. Oral cyclophosphamide can produce a PSA response in up to 30% of patients. A number of experimental approaches are also under study, including inhibition of angiogenesis, growth factors and topoisomerase I; gene therapy; and monoclonal conjugated radionucleides.
BPH update
Interesting data were presented by Dr Claus Roehrborn, Dallas, USA, on the use of baseline PSA to predict growth of the prostate and consequently progression of symptoms and¯ow rate reduction over time. The PSA value acts a surrogate for prostate volume. Since increased prostate volume itself is a risk factor for acute urinary retention, it follows that PSA may also act as a predictor of this complication of BPH.
Studies show that dutasteride produced a 95% reduction in serum dihydrotestosterone levels compared with a 75 ± 80% reduction with ®nasteride. Phase II data indicate that this new compound has similar ef®cacy to ®nasteride with regard to improvement in symptoms and¯ow rates, as well as a comparable adverse event pro®le. Dutasteride is currently being assessed in a large, two-year phase III study involving 3000 men. Results should be available in around 12 months' time.
